List of Peptide Therapies Companies with Phase 4 Active Clinical Trial - 6

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Eusol Biotech was founded in March 2005 in Taipei, Taiwan. The company is involved in the R&D and GMP process development of recombinant human acid fibroblast.

Kissei Pharmaceutical - Approaching R&D with Passion and Creativity “Pharmaceutical company cannot exist without R&D.” These words have been passed down at Kissei ever since the company was founded. They show that R&D is an essential and central part of our work, The phrase also expresses the passion of each and every Kissei Pharmaceutical - Kissei employee for the development of new innovative drugs, in the hope that those drugs will help as many people as possible recover as quickly as possible from disease and live lives full of laughter and joy. We aim to develop and supply innovative pharmaceutical products that contribute to the improvement of medicine and the health of people around the world by aggressive incorporation of leading-edge technology and collaborations with our foreign and domestic partners.

Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India. Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.

Phoenix Nest Biotech is a biotechnology company that focuses on treating Sanfilippo Syndrome by collaborating with leading academics and utilizing licensed key technologies.

Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings. We recently expanded our aesthetics portfolio to include digital services with the acquisition of an innovative fintech platform. We have assembled a team of motivated, talented professionals who collectively aim to transform patient experiences and disrupt the status quo. Exceptional talents with passion, creativity, and dedication to improving lives will immediately contribute to our ambitious pipeline and unique culture. Our employees work on challenging projects in a supportive environment that provides opportunities for growth and development.